CDR2 and cancer: A pivotal change in this system is the replacement of the term “onconeural” with risk-stratified antibody categories, distinguishing “High-risk” antibodies (>70% cancer association, e.g., anti-Hu, anti-Yo) from “Intermediate-risk” antibodies (30–70% cancer association, e.g., anti-NMDAR, anti-GABA-B receptor), thereby reflecting the nuanced oncological associations of surface-directed antibodies [42].